BRCA1/2 testing criteria offer high clinical sensitivity for ATM, PALB2 and CHEK2 carriers in a multigene panel cohort
NCCN BRCA1/2 testing criteria demonstrated high clinical sensitivity when applied to ATM, CHEK2, and PALB2.
Individuals with mutations in ATM, CHEK2, and PALB2 were best captured by criteria without an age limit.
Further investigation of BRCA2, ATM, CHEK2, and PALB2 mutation carriers not meeting any BRCA1/2 testing criteria will help identify further opportunities to improve sensitivity for without significantly compromising specificity